Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
Nutr Metab Cardiovasc Dis. 2012 Sep;22(9):734-40. doi: 10.1016/j.numecd.2010.11.011. Epub 2011 Feb 16.
Elevated iron biomarkers are associated with diabetes and other cardiometabolic abnormalities in the general population. It is unclear whether they are associated with an increased risk of all-cause or cause-specific mortality. The purpose of the current analysis was to evaluate the association of ferritin and transferrin saturation levels with all-cause, cardiovascular, and cancer mortality in the general US adult population.
A prospective cohort study was conducted with 12,258 adults participating in the Third National Health and Nutrition Examination Survey (NHANES III), a nationally representative sample of the US population. Study participants were recruited in 1988-1994 and followed through December 31, 2006 for all-cause, cardiovascular disease, and cancer mortality. The multivariable-adjusted hazard ratios (95% confidence interval) for all-cause mortality comparing the fourth versus the second quartiles of ferritin and transferrin saturation were 1.09 (0.82-1.44; p-trend across quartiles = 0.92) and 1.08 (0.82-1.43; p-trend across quartiles = 0.62), respectively, for men, 1.43 (0.63-3.23; p-trend across quartiles = 0.31) and 1.48 (0.70-3.11; p-trend across quartiles = 0.60), respectively, for premenopausal women, and 1.03 (0.79-1.34; p-trend across quartiles = 0.95) and 1.17 (0.92-1.49; p-trend across quartiles = 0.63), respectively, for postmenopausal women. Quartile of ferritin and transferrin saturation also showed no association between biomarkers of iron status and mortality.
In a large nationally representative sample of US adults, within the spectrum of normal iron metabolism, ferritin and transferrin saturation were not associated with risk of mortality among people who were not taking iron supplements and did not have a baseline history of cardiovascular disease or cancer.
在普通人群中,升高的铁生物标志物与糖尿病和其他心血管代谢异常有关。目前尚不清楚它们是否与全因或特定原因死亡率的增加有关。本分析的目的是评估铁蛋白和转铁蛋白饱和度水平与全因、心血管和癌症死亡率之间的关系,该研究对象为普通美国成年人群。
进行了一项前瞻性队列研究,共有 12258 名成年人参加了第三次全国健康和营养调查(NHANES III),这是美国人口的全国代表性样本。研究参与者于 1988 年至 1994 年招募,并随访至 2006 年 12 月 31 日,以了解全因、心血管疾病和癌症死亡率。与铁蛋白和转铁蛋白饱和度的第四和第二四分位数相比,全因死亡率的多变量调整后的风险比(95%置信区间)分别为 1.09(0.82-1.44;四分位数之间的趋势 p 值=0.92)和 1.08(0.82-1.43;四分位数之间的趋势 p 值=0.62),分别为男性,1.43(0.63-3.23;四分位数之间的趋势 p 值=0.31)和 1.48(0.70-3.11;四分位数之间的趋势 p 值=0.60),分别为绝经前女性,以及 1.03(0.79-1.34;四分位数之间的趋势 p 值=0.95)和 1.17(0.92-1.49;四分位数之间的趋势 p 值=0.63),分别为绝经后女性。铁蛋白和转铁蛋白饱和度的四分位数也显示,铁状态生物标志物与死亡率之间没有关联。
在一个具有代表性的美国成年人的大型全国性样本中,在正常铁代谢范围内,铁蛋白和转铁蛋白饱和度与未服用铁补充剂且无心血管疾病或癌症基线史的人群的死亡率无关。